默沙东与其合作伙伴科伦药业共同研发的肺癌联合疗法，已成功达成一项关键晚期临床试验的主要目标。受此积极消息推动，默沙东股价在盘前交易时段应声上涨3.7%。该疗法在晚期试验中展现出的潜力，为后续的监管审批与商业化进程奠定了坚实基础，也提振了市场对该公司肿瘤管线前景的信心。
默沙东与其合作伙伴科伦药业共同研发的肺癌联合疗法，已成功达成一项关键晚期临床试验的主要目标。受此积极消息推动，默沙东股价在盘前交易时段应声上涨3.7%。该疗法在晚期试验中展现出的潜力，为后续的监管审批与商业化进程奠定了坚实基础，也提振了市场对该公司肿瘤管线前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.